NASDAQ:GRTX

Galera Therapeutics Stock Insider Trading

Healthcare > Biotechnology

Buy GRTX

*Your capital is at risk

$0.100

-0.0010 (-0.99%)

At Close: Jun 03, 2026

Galera Therapeutics Stock Insider Power

Based on the 100 latest insides trades, we have calculated the insider power to be positive at 98.81. In total, the insiders bought 87.48B and sold 2.31B GRTX shares in the last 100 trades. The insider score can be negative despite buy/sell ratio being positive. The score focuses on the quality of the trades.

Insider Power (Last 100 transactions)	98.81
● Buy	87.48B shares
● Sell	2.31B shares
94% Buy Activity Weak Negative Correlation
Buy Signal High Confidence Apr 07, 2026 Analysis Breakdown: Strongly supported by a very high Insider Power Score of 98.81. Confidence increased due to high data reliability score of 90. Supported by overwhelming buy-side pressure (94% buys).

Historical Insider Trades

Date	Type	Person	Role	Amount
May 15, 2026 Sell	Series B Preferred Stock C-Conversion	Emerald Bioventures, Llc 10 Percent Owner	10% Owner	20 814 Value: $0
May 15, 2026 Buy	Common Stock C-Conversion	Emerald Bioventures, Llc 10 Percent Owner	10% Owner	20 813 818 Value: $2.08M
Apr 07, 2026 Buy	Series B Preferred Stock	Emerald Bioventures, Llc 10 Percent Owner	10% Owner	20 813 819 Value: $853.4K
Apr 07, 2026 Buy	Common Stock	Emerald Bioventures, Llc 10 Percent Owner	10% Owner	0 Value: $0
Apr 07, 2026 Buy	Common Stock C-Conversion	Friedman Michael R. Director	Director	5 336 870 Value: $218.8K
Apr 07, 2026 Sell	Series B Preferred Stock C-Conversion	Chang Nancy T	Director	1 181 Value: $0
Apr 07, 2026 Sell	Series B Preferred Stock C-Conversion	Friedman Michael R. Director	Director	5 337 Value: $0
Apr 07, 2026 Buy	Common Stock C-Conversion	Chang Nancy T	Director	1 180 611 Value: $48.4K
Nov 20, 2025 Sell	Common Stock S-Sale	Sorensen Mel President And CEO	CEO / President	70 000 Value: $1K
May 01, 2025 Buy	Stock Option (Right to Buy) A-Award	Sussman Joel F. Chief Accounting Officer	Officer	2 000 000 Value: $44.0K
May 01, 2025 Buy	Stock Option (Right to Buy) A-Award	Sorensen Mel President And CEO	CEO / President	6 000 000 Value: $132.0K
May 01, 2025 Buy	Stock Option (Right to Buy) A-Award	Sorensen Mel President And CEO	CEO / President	6 000 000 Value: $132.0K
May 01, 2025 Buy	Stock Option (Right to Buy) A-Award	Sussman Joel F. Chief Accounting Officer	Officer	2 000 000 Value: $44.0K
Feb 24, 2025 Buy	Stock Option (Right to Buy) A-Award	Lokay Kevin G Director	Director	48 000 Value: $2K
Feb 24, 2025 Buy	Stock Option (Right to Buy) A-Award	Friedman Michael R. Director	Director	96 000 Value: $4K
Feb 24, 2025 Buy	Stock Option (Right to Buy) A-Award	Chang Nancy T	Director	96 000 Value: $4K
Feb 24, 2025 Buy	Stock Option (Right to Buy) A-Award	Alleva Lawrence M Director	Director	48 000 Value: $2K
Feb 24, 2025 Buy	Stock Option (Right to Buy) A-Award	Alleva Lawrence M Director	Director	48 000 Value: $2K
Feb 24, 2025 Buy	Stock Option (Right to Buy) A-Award	Chang Nancy T	Director	96 000 Value: $4K
Feb 24, 2025 Buy	Stock Option (Right to Buy) A-Award	Friedman Michael R. Director	Director	96 000 Value: $4K
Feb 24, 2025 Buy	Stock Option (Right to Buy) A-Award	Lokay Kevin G Director	Director	48 000 Value: $2K
Dec 30, 2024 Buy	Common Stock P-Purchase	Chang Nancy T	Director	7 644 932 Value: $500.0K
Dec 30, 2024 Buy	Series B Preferred Stock A-Award	Chang Nancy T	Director	1 842 Value: $50
Dec 30, 2024 Buy	Common Stock J-Other	Chang Nancy T Insider	Other	0 Value: $0
Dec 30, 2024 Buy	Series B Preferred Stock A-Award	Friedman Michael R. Director	Director	8 326 Value: $225

About Insider Power

Insider Power is a proprietary algorithm developed by StockInvest.us to evaluate the significance of insider transactions. The calculation considers the size, type, and timing of transactions, as well as the insider’s role within the company.

It is important to note that, in general, there is little to no correlation between insider transactions and short-term stock price movements. In one of our studies, only 0.22%^* of stocks with insider activity showed a measurable correlation — and even then, it was unclear whether the effect was caused by insider actions or simply by the stock’s broader trend.

While our algorithms are designed to highlight potentially meaningful signals, these cannot be regarded as statistically significant on their own. Insider trading activity should therefore be seen as informative rather than as direct trading guidance. The Insider Power metric was created to present this information in a clearer and more accessible way, helping investors better understand the possible context of insider activity.

* October 6th, 2025 - Tested on 5562 stocks

ABOUT GALERA THERAPEUTICS, INC.

Galera Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the transformation of radiotherapy in cancer. The company's lead product candidate is avasopasem manganese (GC4419), a small molecule superoxide dismutase mimetic, which has completed Phase III clinical trial for the treatment of radiotherapy induced severe oral mucositis in patients with head and neck cancer...

Read Full Profile Here